A CDMO partnership shows how gene therapy manufacturing is scaling for chronic disease
DDDr. Dereck Mush, MD, MBA
Sep 3
What they do
ShiraTronics designs an active implantable medical device system that delivers electrical stimulation to specific cranial nerves. The system is designed for patients suffering from severe, drug-resistant chronic migraines who require consistent therapeutic intervention.
The record
- Vertical
- Medical Devices
- Sub-segment
- Neuromodulation therapy
- Product type
- Device
- Stage
- Series B
- Headquarters
- Brooklyn Park, USA
- Region
- North America
- Founded
- 2018
- Total funding
- $99M raised
Notable investors: USVP, Ampeak Capital, Aperion Biologics.
Also in Medical Devices
Related on The Signal
CDMOs race to add capacity as cell and gene therapy demand outpaces supply
DDDr. Dereck Mush, MD, MBA
Jan 14The HealthTech Signal
GLP-1 drugs are excellent at losing weight. The muscle question is where healthspan gets decided
GLP-1 drugs are excellent at losing weight. The muscle question is where healthspan gets decided
DDDr. Dereck Mush, MD, MBA
Jul 14The HealthTech Signal
The Top Gene Therapy Breakthroughs of 2026
CRISPR crossed from theory into the clinic. These ten breakthroughs are real, approved and working, and every single one carries the same catch.
DDDr. Dereck Mush, MD, MBA
Jul 5